Stevanato Group Q4 and FY 2025 Financial Results March 4, 2026 Safe Harbor Statement Forward-Looking Statements This presentation contains certain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect the current views of Stevanato Group S.p.A. ("we", "our", "us", "Stevanato Group" or the "Company") and which involve known and unknown risks, uncertainties and assumptions because they relate to events and depend on circumstances that will occur in ...

Financial Performance - Revenue grew by 9% year-over-year (11% at constant currency) in Q3 2025, driven by strong performance in the Biopharmaceutical and Diagnostic Solutions (BDS) segment[12] - High-Value Solutions (HVS) revenue increased by 47% year-over-year, reaching €147.9 million, representing 49% of total revenue[28] - Adjusted EBITDA increased to €77.8 million, with an adjusted EBITDA margin increase of 280 bps to 25.7%[29] - The company maintains its fiscal year 2025 revenue guidance at €1.160 billion - €1.190 billion, implying a growth of 5% to 8%[39] Segment Analysis - The BDS segment revenue increased by 14% (17% at constant currency), with a gross profit margin increase of 400 bps to 32.0%[32] - The Engineering segment revenue decreased by 19% to €36.4 million, with a gross profit margin decrease to 10.4%[34] Capacity Expansion and Investments - The company is expanding capacity for PFS and EZ-fill® cartridges in Latina, Italy, with commercial production expected to launch at the end of FY26[22] - Capital expenditures (CAPEX) for Q3 2025 were €54.9 million[36]

Financial Performance - Revenue grew by 8% year-over-year in Q2 2025, driven by a 10% increase in the BDS (Biopharmaceutical and Diagnostic Solutions) segment, offsetting a 2% decline in the Engineering segment[12, 30] - High-Value Solutions (HVS) accounted for 42% of total revenue in Q2 2025[12] and increased 13% year-over-year to €116.8 million[30] - Gross profit margin increased by 210 bps to 28.1%[31] - Adjusted EBITDA increased to €65.1 million, with an adjusted EBITDA margin increase of 240 bps to 23.2%[31] - Net profit was €29.7 million, or €0.11 of diluted EPS[31] Segment Performance - BDS segment revenue increased by 10% to €244 million, with a gross profit margin increase of 350 bps to 31.2%[33, 34, 35] - Engineering segment revenue decreased by 2% to €36.5 million, with a gross profit margin decrease to 6.6%[36, 37] Capacity Expansion and Investments - Capital expenditure (CAPEX) in Q2 2025 was €69.1 million[40] - Net cash generated from operations in Q2 2025 was €44.9 million[40] - Free cash flow in Q2 2025 was negative €13.0 million[40] - The company announced financing agreements totaling €200 million to support capacity expansion in Latina and Fishers facilities[40] Outlook - The company maintains its FY 2025 revenue guidance of €1.160 billion - €1.190 billion, representing a year-over-year growth of 5% to 8%[42] - The company expects HVS to account for 40% to 42% of revenue in FY 2025[42] - Adjusted diluted EPS is projected to be €0.50 - €0.54 for FY 2025[42] - Adjusted EBITDA is projected to be €288.5 million - €301.8 million for FY 2025[42]